Karyopharm Therapeutics (KPTI)
(Delayed Data from NSDQ)
$1.13 USD
+0.05 (4.63%)
Updated May 3, 2024 04:00 PM ET
After-Market: $1.12 -0.01 (-0.88%) 7:58 PM ET
3-Hold of 5 3
F Value B Growth C Momentum D VGM
Balance Sheet
Fiscal Year End for Karyopharm Therapeutics Inc falls in the month of December.
All items in Millions except Per Share data.
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | 192 | 279 | 235 | 252 | 263 |
Receivables | 27 | 47 | 23 | 13 | 8 |
Notes Receivable | 0 | 0 | 0 | 0 | 0 |
Inventories | 3 | 4 | 4 | 3 | 0 |
Other Current Assets | 12 | 20 | 14 | 9 | 7 |
Total Current Assets | 234 | 350 | 276 | 277 | 279 |
Net Property & Equipment | 1 | 1 | 2 | 2 | 3 |
Investments & Advances | 0 | 0 | 0 | 24 | 2 |
Other Non-Current Assets | 0 | 0 | 0 | 0 | 0 |
Deferred Charges | 0 | 0 | 0 | 0 | 0 |
Intangibles | 0 | 0 | 0 | 0 | 0 |
Deposits & Other Assets | 2 | 1 | 20 | 1 | 1 |
Total Assets | 240 | 358 | 305 | 313 | 295 |
Liabilities & Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Notes Payable | 0 | 0 | 0 | 0 | 0 |
Accounts Payable | 3 | 3 | 2 | 4 | 1 |
Current Portion Long-Term Debt | 0 | 0 | 0 | 0 | 0 |
Current Portion Capital Leases | 0 | 0 | 0 | 0 | 0 |
Accrued Expenses | 61 | 58 | 69 | 53 | 41 |
Income Taxes Payable | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities | 2 | 2 | 1 | 1 | 3 |
Total Current Liabilities | 69 | 66 | 74 | 60 | 46 |
Mortgages | 0 | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | 0 | 0 | 0 | 0 | 2 |
Convertible Debt | 171 | 170 | 169 | 118 | 110 |
Long-Term Debt | 0 | 0 | 0 | 0 | 0 |
Non-Current Capital Leases | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 133 | 133 | 133 | 73 | 74 |
Minority Interest (Liabilities) | 0 | 0 | 0 | 0 | 0 |
Total Liabilities | 377 | 375 | 385 | 263 | 245 |
Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Preferred Stock | 0 | 0 | 0 | 0 | 0 |
Common Stock (Par) | 0 | 0 | 0 | 0 | 0 |
Capital Surplus | 1,351 | 1,328 | 1,099 | 1,120 | 923 |
Retained Earnings | -1,487 | -1,344 | -1,179 | -1,070 | -873 |
Other Equity | 0 | -1 | 0 | 1 | 0 |
Treasury Stock | 0 | 0 | 0 | 0 | 0 |
Total Shareholder's Equity | -136 | -17 | -80 | 51 | 50 |
Total Liabilities & Shareholder's Equity | 240 | 358 | 305 | 313 | 295 |
Total Common Equity | -136 | -17 | -80 | 51 | 50 |
Shares Outstanding | 114.50 | 113.20 | 75.50 | 73.60 | 62.70 |
Book Value Per Share | -1.19 | -0.15 | -1.06 | 0.69 | 0.79 |
Fiscal Year End for Karyopharm Therapeutics Inc falls in the month of December.
All items in Millions except Per Share data.
3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | 3/31/2023 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | -99,999 | 192 | 209 | 237 | 261 |
Receivables | NA | 27 | 38 | 32 | 35 |
Notes Receivable | NA | 0 | 0 | 0 | 0 |
Inventories | NA | 3 | 3 | 4 | 4 |
Other Current Assets | NA | 12 | 13 | 18 | 18 |
Total Current Assets | NA | 234 | 263 | 291 | 319 |
Net Property & Equipment | NA | 1 | 1 | 1 | 1 |
Investments & Advances | NA | 0 | 0 | 0 | 0 |
Other Non-Current Assets | NA | 0 | 0 | 0 | 0 |
Deferred Charges | NA | 0 | 0 | 0 | 0 |
Intangibles | NA | 0 | 0 | 0 | 0 |
Deposits & Other Assets | NA | 2 | 1 | 0 | 1 |
Total Assets | NA | 240 | 270 | 298 | 326 |
Liabilities & Shareholders Equity | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | 3/31/2023 |
---|---|---|---|---|---|
Notes Payable | NA | 0 | 0 | 0 | 0 |
Accounts Payable | NA | 3 | 1 | 2 | 9 |
Current Portion Long-Term Debt | NA | 0 | 0 | 0 | 0 |
Current Portion Capital Leases | NA | 0 | 0 | 0 | 0 |
Accrued Expenses | NA | 61 | 56 | 52 | 47 |
Income Taxes Payable | NA | 0 | 0 | 0 | 0 |
Other Current Liabilities | NA | 2 | 2 | 2 | 3 |
Total Current Liabilities | NA | 69 | 62 | 59 | 62 |
Mortgages | NA | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | NA | 0 | 0 | 0 | 0 |
Convertible Debt | NA | 171 | 171 | 171 | 170 |
Long-Term Debt | NA | 0 | 0 | 0 | 0 |
Non-Current Capital Leases | NA | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | NA | 134 | 135 | 134 | |
Minority Interest (Liabilities) | NA | 0 | 0 | 0 | 0 |
Total Liabilities | NA | 377 | 370 | 369 | 371 |
Shareholders Equity | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | 3/31/2023 |
---|---|---|---|---|---|
Preferred Stock | NA | 0 | 0 | 0 | 0 |
Common Stock (Par) | NA | 0 | 0 | 0 | 0 |
Capital Surplus | NA | 1,351 | 1,346 | 1,340 | 1,333 |
Retained Earnings | NA | -1,487 | -1,445 | -1,411 | -1,378 |
Other Equity | NA | 0 | -1 | -1 | 0 |
Treasury Stock | NA | 0 | 0 | 0 | 0 |
Total Shareholder's Equity | NA | -136 | -100 | -71 | -45 |
Total Liabilities & Shareholder's Equity | NA | 240 | 270 | 298 | 326 |
Total Common Equity | 0 | -136 | -100 | -71 | -45 |
Shares Outstanding | 115.00 | 114.50 | 114.50 | 114.30 | 114.00 |
Book Value Per Share | 0.00 | -1.19 | -0.88 | -0.62 | -0.40 |